FORM 4	4
--------	---

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person <sup>+</sup> Kent Stephen B H	2. Issuer Name and ENZO BIOCHE			•••		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) C/O ENZO BIOCHEM, INC., 527 AVENUE	( DIGONI	3. Date of Earliest Tr 01/24/2008	ansaction (N	Month	h/Day/Yea	ır)		Officer (give title below) Ot	her (specify belo	w)
(Street) NEW YORK CITY, NY 10022		4. If Amendment, Da	te Original	Filed	(Month/Day/	Year)		6. Individual or Joint/Group Filing(Chec _X_Form filed by One Reporting Person Form filed by More than One Reporting Perso		ne)
(City) (State)	(Zip)	,	Table I - No	on-De	erivative S	Securitie	s Acqu	iired, Disposed of, or Beneficially Owr	ied	
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		(Instr. 8)	tion	4. Securi (A) or Di (Instr. 3,	isposed o	f(D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	Form:	7. Nature of Indirect Beneficial
		(Month/Day/Year)	Code	v	Amount	(A) or (D)	Price	(Instr. 3 and 4)	Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained SEC 1474 (9-02) in this form are not required to respond unless the form displays a currently valid OMB control number.

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

			()	e.g., puts	i, ca	ns, warra	ints,	options, con	vertible securit	lies)					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	tion )	5. Numbor of Deriva Securitie Acquired or Dispos of (D) (Instr. 3, and 5)	ative s l (A) sed	(Month/Day	Date /Year)	7. Title and of Underlyin Securities (Instr. 3 and	ıg	Derivative Security (Instr. 5)	Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form of Derivative Security: Direct (D) or Indirect	Beneficial Ownership
				Code	v	(A)	(D)	Exercisable	Expiration Date	Title	Amount or Number of Shares		(1150.4)	(11150.4)	
Restricted Stock Units (1)	<u>(1)</u>	01/24/2008		А		12,328		<u>(1)</u>	01/24/2018	Common Stock <sup>(1)</sup>	12,328	(1)	3,500 <sup>(2)</sup>	D	

## **Reporting Owners**

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Kent Stephen B H C/O ENZO BIOCHEM, INC. 527 MADISON AVENUE NEW YORK CITY, NY 10022	Х						

### **Signatures**

 /s/ Stephen B.H. Kent
 01/24/2008

 Signature of Reporting Person
 Date

# **Explanation of Responses:**

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) January 24, 2008, the Reporting Person was granted 12,328 Restricted Stock Units as compensation for serving as an independent director of the Issuer. Each Restricted Stock Unit consists of a right to the issuance of one share of common stock, par value \$.01 ("Common Stock"). The Restricted Stock Units are subject to a two-year vesting period.

(2) The Reporting Person also owns 15,828 Restricted Stock Units that will not vest within 60 days.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.